The Outlook For The Pharmaceutical Industry Under Trump

Law360, New York (January 12, 2017, 1:30 PM EST) -- Mark P. Goodman

Jennifer L. Chu

Kevin A. Rinker The 2016 election will have important consequences for the pharmaceutical industry. While President-elect Trump has now made key health care-related appointments and has issued several broad post-election statements related to health care reform, many unknowns remain.

Immediately after the election, the price of pharmaceutical and biotech companies generally rose. Investors have been optimistic that Mr. Trump's free-market, anti-regulation approach will benefit drug and biotech manufacturers.

While there is truth to this conventional wisdom, what we do know suggests that the reality will be more nuanced. We also know that changes won't be...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!